Cocrystal Pharma Inc
(NASDAQ : COCP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Generic
symbolcompany%chnglast%shortavg$volume
AGNAllergan plc
1.91%186.452.8%$357.73m
TEVATeva Pharmaceutical Industries Limited Sponsored ADR
1.44%22.052.1%$303.18m
ZTSZoetis, Inc. Class A
1.54%91.471.9%$198.17m
MYLMylan N.V.
1.82%32.963.2%$171.95m
TXMDTherapeuticsMD, Inc.
4.69%5.8125.8%$16.28m
RDYDr. Reddy's Laboratories Ltd. Sponsored ADR
2.03%35.152.0%$9.72m
ABEOAbeona Therapeutics, Inc.
2.59%10.477.9%$7.34m
TAROTaro Pharmaceutical Industries Ltd.
-0.36%94.406.3%$4.22m
KINKindred Biosciences, Inc.
6.55%13.020.3%$2.68m
JAGXJaguar Animal Health, Inc.
11.55%0.579.8%$2.46m
LFVNLifeVantage Corporation
3.15%10.803.3%$1.65m
PETXAratana Therapeutics, Inc.
1.31%5.428.7%$1.42m
CPHIChina Pharma Holdings, Inc.
-1.96%0.240.1%$0.07m

Company Profile

Cocrystal Pharma, Inc. is a clinical stage biotechnology company, which engages in discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of Hepatitis C. Phase 1b studies in Hepatitis C infected patients showed the largest reduction in viral load of any non-neoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 6 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the company has a pipeline of early preclinical programs. Cocrystal Pharma was founded on January 2, 2014 and is headquartered in Tucker, GA..